MENLO PARK, Calif., July 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make GRAIL's Galleri® multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galler

Funding to accelerate U.S., European and Middle East commercialization and collect clinical evidence for U.S. weight loss marketing indication GOSSELIES, Belgium, July 16, 2026 /PRNewswire/ -- Endo Tools Therapeutics (ETT), developers of advanced endoscopic medical devices, today announced the closing of its Series C financing round, raising € 20 million (c. $ 23 million) to advance U.S., European and Middle East commercialization of the endomina® platform, including the recently FDA-cleared end

ACLM applauds CMS' proposed changes that emphasize chronic disease prevention, behavioral health, and transformation of primary care for Medicare beneficiaries. ST. LOUIS, July 16, 2026 /PRNewswire/ -- The American College of Lifestyle Medicine (ACLM) welcomes the Centers for Medicare and Medicaid Services' (CMS) Physician Fee Schedule proposed rule announced yesterday, which includes long-awaited provisions that can provide greater access to lifestyle medicine for Medicare beneficiaries and imp

An innovative blood pressure wearable that works seamlessly with your day SAN FRANCISCO, July 16, 2026 /PRNewswire/ -- Signal Ring today launches as the first wearable designed to measure and understand blood pressure without the squeeze, noise or setup of a traditional cuff. Blood pressure is one of the body's most important health signals. It changes all day with stress, sleep, movement and meals. Yet most people still capture it the way their parents did: a cuff that tightens around the arm f

NEW YORK--(BUSINESS WIRE)--Kalshi, the next-generation financial exchange, today announced a partnership with public intelligence company AppliedXL to launch a pilot suite of prediction markets on clinical trial outcomes and FDA regulatory decisions. The markets will create publicly available, accurate probabilities aiming to help solve drug development's information silo problem. The odds that a drug will succeed are among the most valuable numbers in the economy, and among the least visible. T

BEIJING, July 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Phase II portion of the Phase II/III trial of its TYK2 inhibitor Soficitinib (ICP-332) for non-segmental vitiligo has met the primary endpoint. The study is a Phase II/III randomized, double-blind, placebo-controlled, parallel-group, adaptive, multicenter clinical trial. The study consis

Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹ GALWAY, Ireland, July 16, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain managemen

SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with Oxford Finance LLC ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders exp

艾博生物首席人工智能官 Iain McFadyen 博士受邀出席7月20日至22日于美国波士顿举办的第六届mRNA疗法年度峰会 (6th Annual mRNA-Based Therapeutics Summit)。 作为融合前沿突破、战略合作与行业洞见的顶尖平台，本届大会将系统梳理mRNA技术从药物设计、递送创新到临床转化与商业化的全产业链发展路径，旨在推动mRNA领域的科学创新与医药合作，加速将前沿发现转化为可规模化生产且经临床验证的疗法（Accelerate Emerging Discoveries into Scalable & Clinically Validated Therapies Through Scientific Innovation & Biopharma Collaborations）。 大会汇聚了全球生物医药生态圈的核心力量，不仅邀请到美国FDA/CBER、欧洲EMA、英国MHRA等全球权威监管机构和流行病防范创新联盟CEPI等多边合作机构深度参与，还吸引了包括AstraZeneca、Pfizer、GSK、Sanofi、Merck & Co在内的全球制药巨头

点击蓝字 关注我们 编者按：盛夏聚冰城，十载启新程。2026年7月10日至12日，“中国临床肿瘤学会（CSCO）第十届血液肿瘤学术大会”在哈尔滨盛大召开。历经十载砥砺深耕，CSCO血液肿瘤学术大会已成为我国血液肿瘤领域重要的学术交流平台。本届大会既是对过往十年辉煌历程的回顾与致敬，更是立足创新、面向未来的重要里程碑。会议期间，《肿瘤瞭望-血液时讯》特邀北京高博博仁医院张亚晶主任接受采访，围绕血液肿瘤免疫治疗的发展趋势、临床创新评价、复杂患者治疗策略及全生命周期管理等热点话题分享真知灼见，深入探讨如何以系统化、精准化的临床决策优化治疗路径，助力患者实现更长生存与更高质量获益。 《肿瘤瞭望-血液时讯》 近年来，CAR-T、双特异性抗体及新型靶向药物快速发展，新的靶点和产品不断涌现。您认为，未来血液肿瘤免疫治疗的核心竞争，是否仍然是新靶点和新产品之间的竞争？下一阶段真正决定患者长期获益的关键因素是什么？ 张亚晶主任 北京高博博仁医院 我认为，下一阶段免疫治疗的竞争，表面上看是新靶点、新结构和新产品的竞争，实质上则是临床系统认知能力的竞争。 过去，我们评价一种治疗往往关注缓解率有多高、起效有多